Incidence and predictors of permanent pacemaker implantation after surgical aortic v alve replacement: Data of the Netherlands Heart Registration (NHR)

Ravaux, Justine M.; Kuijk, Sander MJ van; Mauro, Michele Di; Vernooy, Kevin; Bidar, Elham; Mariani, Silvia; Dato, Giulia Actis; Hof, Arnoud W van ’t; Veenstra, Leo; Kats, Suzanne; Houterman, Saskia; Lorusso, Roberto

doi:10.1111/jocs.15803

Cited by 6 publications

(6 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One patient was implanted due to new onset of critical bradycardia, and the second patient required CRT‐PM implantation due to worsening heart failure. The rate of new PM implantation after TAVR can vary in a wide range, from 3.4% 28 to as high as 25.9%–32.8% 5,29,30 . Taking this into account, our pacemaker implantation rate seems high, but still within the expected range, based on the literature.…”

Section: Discussionmentioning

confidence: 69%

Single center experience with the balloon‐expandable Myval transcatheter aortic valve system with the first 100 patients: 30‐day and 1‐year follow‐up

Magyari,

Kittka,

Goják

et al. 2023

Cathet Cardio Intervent

View full text Add to dashboard Cite

AimsTo report our single‐center data, regarding the first 100 patients who underwent TAVR procedure with the new balloon‐expandable MYVAL system. We report 30‐day and 1‐year outcomes in low to high‐risk TAVR patient population.MethodsFrom November 2019 to July 2021, 100 consecutive patients underwent TAVR procedure. Patient outcome was classified according to the VARC‐2 definitions. The device performance was assessed using transthoracic echocardiography. Data collection was allowed by the Local Ethical Committee.ResultsThe mean age was 74.7 years, 63 (63%) were male. The mean Euroscore II and STS score were 4.8 ± 4.9 and 5.6 ± 3.9, respectively. Transfemoral access was the most frequent (surgical vs. percutaneous 2% vs. 97%) and in one patient surgical subclavian access was used. VARC‐2 outcomes were as follows: device success 99%, STROKE 1%, major and minor vascular complication was 1% and 11%, respectively, the rate of new permanent pacemaker implantation was 30.7%. At discharge, the incidence of grade I, grade II aortic regurgitation was 39% and 1%, respectively, without relevant PVL. In‐hospital mortality was only 1%. These results included a high proportion (17%) of patients with bicuspid aortic valves. At 1 year, the all‐cause mortality rate was 7% (only two due to cardiac event) and only a single patient had valve‐related dysfunction requiring surgical aortic replacement.ConclusionsTAVR procedure with MYVAL transcatheter heart valve system shows excellent 30‐day and 1‐year outcomes regarding patient survival, technical success, and valve‐related adverse events. The limitations of our study comprise a single‐center study with retrospective data collection.

show abstract

Section: Discussionmentioning

confidence: 69%

Single center experience with the balloon‐expandable Myval transcatheter aortic valve system with the first 100 patients: 30‐day and 1‐year follow‐up

Magyari,

Kittka,

Goják

et al. 2023

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

“…[ 32 ] In contrast, the risk of needing a permanent pacemaker after SAVR is approximately 4%. [ 33 ]…”

Section: Permanent Pacemakermentioning

confidence: 99%

Treatment of Severe Aortic Valve Stenosis: Impact of Patient Sex and Life Expectancy on Treatment Choice

Rashedi

Otto

2022

Eur Cardiol

View full text Add to dashboard Cite

In adults with severe aortic stenosis, sex and age differences in symptoms and diagnosis may lead to delays in intervention. Choice of intervention partly depends on expected longevity because bioprosthetic valves have limited durability, particularly in younger patients. Current guidelines recommend the following: a mechanical valve in younger adults (aged <50 years) if lifelong anticoagulation is possible and acceptable and a valve-sparing procedure is not possible; surgical mechanical or bioprosthetic aortic valve replacement (SAVR) in adults aged 50–65 years; and transcatheter aortic valve implantation (TAVI) for those aged >80 years based on lower mortality and morbidity compared to SAVR and adequate valve durability. For patients aged 65–80 years, the choice between TAVI and a bioprosthetic SAVR depends on expected longevity, which is greater in women than men, as well as associated cardiac and noncardiac conditions, valvular and vascular anatomy, estimated risk of SAVR versus TAVI and expected complications and patient preferences.

show abstract

“…To editor, There is scarcity of nationwide data for the predictors and clinical implication of permanent pacemaker implantation (PPI) following surgical aortic valve replacement (SAVR). Ravaux et al 1…”

Section: Predictors Of Permanent Pacemaker Implantation Following Surgical Aortic Valve Replacementmentioning

confidence: 99%

Predictors of permanent pacemaker implantation following surgical aortic valve replacement

Miyauchi

Imamura

2021

Journal of Cardiac Surgery

View full text Add to dashboard Cite

Incidence and predictors of permanent pacemaker implantation after surgical aortic v alve replacement: Data of the Netherlands Heart Registration (NHR)

Cited by 6 publications

References 36 publications

Single center experience with the balloon‐expandable Myval transcatheter aortic valve system with the first 100 patients: 30‐day and 1‐year follow‐up

Single center experience with the balloon‐expandable Myval transcatheter aortic valve system with the first 100 patients: 30‐day and 1‐year follow‐up

Treatment of Severe Aortic Valve Stenosis: Impact of Patient Sex and Life Expectancy on Treatment Choice

Predictors of permanent pacemaker implantation following surgical aortic valve replacement

Contact Info

Product

Resources

About